ISSN: 1300-7777 E-ISSN: 1308-5263
Failure of yttrium-90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (Zevalin®) with fatal side effects in relapsed/refractory diffuse large B-cell NHL transformed from other lymphomas [Turk J Hematol]
Turk J Hematol. 2008; 25(4): 207-208

Failure of yttrium-90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (Zevalin®) with fatal side effects in relapsed/refractory diffuse large B-cell NHL transformed from other lymphomas

Songül Şerefhanoğlu, Ebru Koca, Hakan Goker, İbrahim Celalettin Haznedaroğlu, Deniz Çetiner, Nilgün Sayınalp, Yahya Büyükaşık, Osman İlhami Özcebe
Department Of Internal Medicine, Division Of Hematology, Hacettepe University School Of Medicine, Ankara, Turkey

Keywords: Ibritumomab Tiuxetan Radioimmunotherapy, NHL


Diğer lenfomalardan transforme olmuş relaps/refrakter difüz büyük B hücreli lenfomada ölümcül yan etkisi ile yttrium-90(90Y)-ibritumomab tiuxetan radyoimmunoterapi (Zevalin®)`nin başarısızlığı

Songül Şerefhanoğlu, Ebru Koca, Hakan Goker, İbrahim Celalettin Haznedaroğlu, Deniz Çetiner, Nilgün Sayınalp, Yahya Büyükaşık, Osman İlhami Özcebe
Department Of Internal Medicine, Division Of Hematology, Hacettepe University School Of Medicine, Ankara, Turkey



Songül Şerefhanoğlu, Ebru Koca, Hakan Goker, İbrahim Celalettin Haznedaroğlu, Deniz Çetiner, Nilgün Sayınalp, Yahya Büyükaşık, Osman İlhami Özcebe. Failure of yttrium-90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (Zevalin®) with fatal side effects in relapsed/refractory diffuse large B-cell NHL transformed from other lymphomas. Turk J Hematol. 2008; 25(4): 207-208

Corresponding Author: Songül Şerefhanoğlu, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2016) = 0.686